DR. KATISHA T VANCE M.D. NPI 1467526442

NPI Details

DR. Katisha T Vance, M.D. is a hematology and oncology internal medicine in Birmingham, AL with 26 years of experience. The provider is an internist doctor of osteopathy that specializes in the treatment of the combination of hematology and oncology disorders. A doctor of osteopathy that is board eligible/certified by the American Osteopathic Board of Internal Medicine WAS able to obtain a Certificate of Special Qualifications in the field of Hematology and Oncology. The Certificate is NO longer offered. DR. Katisha T Vance, M.D. NPI is 1467526442. The provider is registered as an individual entity type.

The NPPES NPI record indicates the provider is a female.

Education
Medical School: UNIVERSITY OF ALABAMA SCHOOL OF MEDICINE
Graduation Year:2000

The provider's business location address is:

833 PRINCETON AVE SW STE 105A
POB III
BIRMINGHAM, AL
ZIP 35211-323
Phone: (205) 786-6983
Fax: (205) 786-6987

The NPI 1467526442 is registered in the Medicare Provider, Enrollment, Chain and Ownership System (PECOS). The provider is legally eligible to order and refer Part B (Clinical Laboratory and Imaging), Durable Medical Equipment, Part A Home Health Agency (HHA), Power Mobility Devices.

The following top HCPCS codes were publicly reported for this provider under the Medicare program for the year 2016. The reported codes are based on the top codes for each available Medicare specialty, excluding evaluation and management codes.

• Injection, ferumoxytol, for treatment of iron deficiency anemia, 1 mg (non-esrd use) (HCPCS:Q0138)
• Injection, aprepitant, 1 mg (HCPCS:J0185)
• Injection, denosumab, 1 mg (HCPCS:J0897)
• Injection, darbepoetin alfa, 1 microgram (non-esrd use) (HCPCS:J0881)
• Injection, dexamethasone sodium phosphate, 1 mg (HCPCS:J1100)
• Injection, palonosetron hcl, 25 mcg (HCPCS:J2469)
• Insertion of needle into vein for collection of blood sample (HCPCS:36415)
• Infusion into a vein for therapy, prevention, or diagnosis, additional sequential infusion, 1 hour or less (HCPCS:96367)
• Complete blood cell count (red cells, white blood cell, platelets), automated test and automated differential white blood cell count (HCPCS:85025)
• Injection, pegfilgrastim, excludes biosimilar, 0.5 mg (HCPCS:J2506)
• Administration of chemotherapy into vein, 1 hour or less (HCPCS:96413)
• Injection of additional new drug or substance into vein (HCPCS:96375)
• Infusion into a vein for hydration, each additional hour (HCPCS:96361)
• Established patient office or other outpatient visit, 30-39 minutes (HCPCS:99214)
• Infusion, normal saline solution, 250 cc (HCPCS:J7050)
• Injection of drug or substance under skin or into muscle (HCPCS:96372)
• Infusion into a vein for therapy, prevention, or diagnosis, 1 hour or less (HCPCS:96365)
• Injection, diphenhydramine hcl, up to 50 mg (HCPCS:J1200)
• Established patient office or other outpatient visit, 20-29 minutes (HCPCS:99213)
• Administration of additional new drug or substance into vein, 1 hour or less (HCPCS:96417)
• Injection, methylprednisolone sodium succinate, up to 125 mg (HCPCS:J2930)
• Established patient office or other outpatient visit, 40-54 minutes (HCPCS:99215)
• Administration of chemotherapy into vein, each additional hour (HCPCS:96415)
• Application of on-body injector for under skin injection (HCPCS:96377)
• Irrigation of implanted venous access drug delivery device (HCPCS:96523)
• Injection, vitamin b-12 cyanocobalamin, up to 1000 mcg (HCPCS:J3420)
• Oncology care model (ocm) monthly enhanced oncology services (meos) payment for ocm enhanced services. g9678 payments may only be made to ocm practitioners for ocm beneficiaries for the furnishment of enhanced services as defined in the ocm participation a (HCPCS:G9678)
• Follow-up hospital inpatient care per day, typically 25 minutes (HCPCS:99232)
• Initial hospital inpatient care per day, typically 30 minutes (HCPCS:99221)
• New patient office or other outpatient visit, 60-74 minutes (HCPCS:99205)
• Initial hospital inpatient care per day, typically 50 minutes (HCPCS:99222)
• Severe acute respiratory syndrome coronavirus 2 (covid-19) vaccine, mrna-lnp, spike protein, preservative free, 100 mcg/0.5ml dosage, for intramuscular use (HCPCS:91301)

The enumeration date for this NPI number is 11/20/2006 and was last updated on 6/4/2015.

Taxonomy Codes

The NPI record includes the healthcare provider taxonomy classification, state license number and state of licensure. The following information regarding the scope of practice of this provider is available:

Other Identifiers

The following information regarding additional identifiers associated to this NPI record includes the other identifier number, identifier type, identifier state and issuer.